Tolebrutinib did not show superiority over Aubagio (teriflunomide) in reducing relapse rates or MRI-detected inflammatory ...

Elizabeth: Staying in NEJM then, let's turn to this examination of a new medicine for relapsing multiple sclerosis -- it's called tolebrutinib -- and an existing medicine it's compared against ...

The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved ...

"Without that [Agency for Healthcare Research and Quality] support, we will become ineffective." -- former U.S. Preventive ...

--U.S. FDA Delays: Sanofi is potentially exposed to any delays in reviews due to recently announced staff firings at the U.S. Food and Drug Administration. Its anti-inflammatory drug Dupixent was ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

The annual meeting of the American Academy of Neurology was held this year from April 5 to 9 in San Diego. Participants ...

Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534] Technology appraisal guidance Tislelizumab ...

A Cleveland Clinic-led clinical trial of tolebrutinib ... in patients with non-relapsing secondary progressive multiple sclerosis (SPMS).

People with multiple sclerosis (MS) who live in rural areas ... effective at controlling… Sanofi‘s oral BTK inhibitor tolebrutinib significantly delayed the onset of six-month confirmed ...